Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Completed 12Recruiting 5Active not recruiting 4Withdrawn 2Terminated 2

Sponsor Class

OTHER 8INDUSTRY 4NIH 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1

Interventions

pembrolizumab 185Carboplatin 133Paclitaxel 102Cisplatin 102Gemcitabine 86Pemetrexed 80durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 42Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × polatuzumab vedotin × Clear all
NCT05171647 2026-05-07

SUNMO

Hoffmann-La Roche

Phase 3 Active not recruiting
208 enrolled 12 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT05954910 2026-05-01

A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

Hoffmann-La Roche

Active not recruiting
1,000 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 1/2 Active not recruiting
211 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT03671018 2024-11-29

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1/2 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡